Zymeworks BC Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-12-10: Form 8-K; Period of report 2018-12-08; Description 8.01 Other Events; Details 8.01.
- 2018-12-06: Form 8-K/A; Period of report 2018-11-26; Description 8.01 Other Events; Details 8.01.
- 2018-11-27: Form 8-K; Period of report 2018-11-26; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2018-11-14: Form 8-K; Period of report 2018-11-14; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-12-10 | 8-K | 2018-12-08 | 8.01 Other Events | 8.01 On December 8, 2018, Zymeworks Inc. announced the presentation of IND-enabling data for ZW49, its novel biparatopic HER2-targeted ADC, at the San Antonio Breast Cancer Symposium in San Antonio, Texas. | form8k.htm |
| 2018-12-06 | 8-K/A | 2018-11-26 | 8.01 Other Events | 8.01 On November 27, 2018, Zymeworks Inc. (the “Company”) filed a current report on Form 8-K (the “Current Report”) regarding entry into the following agreements with BeiGene, Ltd. (“BeiGene”): (i) two license and collaboration agreements (the “ZW25 Agreement” and the “ZW49 Agreement” and together, the “Product Candidate Agreements”); and (ii) a research and license agreement (the “Platform Agreement” and together with the Product Candidate Agreements, the “BeiGene Agreements”). | form8-ka.htm |
| 2018-11-27 | 8-K | 2018-11-26 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On November 26, 2018, Zymeworks Inc. (“Zymeworks”) entered into the following agreements with BeiGene, Ltd. (“BeiGene”): (i) two license and collaboration agreements (the “ZW25 Agreement” and the “ZW49 Agreement” and together, the “Product Candidate Agreements”) granting BeiGene exclusive rights to research, develop, and commercialize Zymeworks’ product candidates, ZW25 and ZW49, in Asia (excluding Japan but including the People’s Republic of China, South Korea and other countries), Australia and New Zealand (together, the “BeiGene Territory”); and (ii) a research and license agreement granting BeiGene rights to research, and exclusive rights to develop and commercialize globally up to three bispecific antibodies generated through the use of Zymeworks’ AzymetricTM and EFECTTM platforms (the “Platform Agreement” and together with the Product Candidate Agreements, the “BeiGene Agreements”). 8.01 On November 27, 2018, Zymeworks issued a press release announcing the BeiGene Agreements, which was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. | d596335d8k.htm |
| 2018-11-14 | 8-K | 2018-11-14 | 8.01 Other Events | 8.01 On November 14, 2018, Zymeworks Inc. announced the presentation of updated ZW25 clinical data by Murali Beeram, MD, a clinical investigator at the START Center for Cancer Care, San Antonio, Texas. | form8k.htm |
| 2018-11-07 | 8-K | 2018-11-07 | 8.01 Other Events | 8.01 On November 7, 2018, Zymeworks Inc. (the “Company”) announced that that management will present at the upcoming Stifel 2018 Healthcare Conference taking place November 13-14, 2018 in New York, NY and at the Jefferies 2018 London Healthcare Conference taking place November 14-15, 2018 in London, England. | form8-k.htm |
| 2018-11-06 | 8-K | 2018-11-06 | 2.02 Results of Operations and Financial Condition | 2.02 On November 6, 2018, Zymeworks Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2018. | d541670d8k.htm |
| 2018-10-30 | 8-K | 2018-10-30 | 8.01 Other Events | 8.01 On October 30, 2018, Zymeworks Inc. (the “Company”) announced that its abstract describing new data from the Company’s adaptive Phase 1 clinical trial for ZW25 has been selected for a plenary session presentation at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held in Dublin, Ireland from November 13-16, 2018. | form8k.htm |
| 2018-10-26 | 8-K | 2018-10-23 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On October 23, 2018, Zymeworks Inc. (“Zymeworks”) entered into a research and license agreement (the “Agreement”) with LEO Pharma A/S (“LEO Pharma”) pursuant to which the companies will collaborate on the discovery of monospecific antibodies to develop bispecific therapeutics targeting cytokine-receptor pathways using Zymeworks’ antibody discovery capabilities and its proprietary AzymetricTM and EFECTTM platforms. 8.01 On October 23, 2018, Zymeworks issued a press release announcing the Agreement, which was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. | form8k.htm |
| 2018-10-04 | 8-K | 2018-10-04 | 8.01 Other Events | 8.01 On October 4, 2018, Zymeworks Inc. announced that it will webcast its R&D Briefing from 9:00 a.m. to 12:00 p.m. | form8k.htm |
| 2018-09-25 | 8-K | 2018-09-25 | 8.01 Other Events | 8.01 On September 25, 2018, Zymeworks Inc. announced that management will present at the upcoming Ladenburg Thalmann 2018 Healthcare Conference taking place October 1-2, 2018 in New York, NY. | form8k.htm |
| 2018-09-19 | 8-K | 2018-09-19 | 8.01 Other Events | 8.01 On September 19, 2018, Zymeworks Inc. announced the naming of Anthony Polverino, Ph.D., as Executive Vice President of Early Development and Chief Scientific Officer. | form8-k.htm |
| 2018-09-04 | 8-K | 2018-09-04 | 8.01 Other Events | 8.01 On September 4, 2018, Zymeworks Inc. announced the achievement of a development milestone in its collaboration with Eli Lilly and Company. | form8k.htm |
| 2018-08-29 | 8-K | 2018-08-29 | 8.01 Other Events | 8.01 On August 29, 2018, the Company announced that management will present at the upcoming 13th Annual Wells Fargo Securities Healthcare Conference taking place September 5-6, 2018 in Boston, MA. | form8-k.htm |
| 2018-08-02 | 8-K | 2018-08-02 | 8.01 Other Events | 8.01 On August 2, 2018, the Company announced that management will present at the upcoming Canaccord Genuity 38th Annual Growth Conference taking place August 8-9, 2018 in Boston, MA, USA. | d594381d8k.htm |
| 2018-08-01 | 8-K | 2018-08-01 | 2.02 Results of Operations and Financial Condition | 2.02 On August 1, 2018, Zymeworks Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2018. | d597389d8k.htm |
| 2018-06-14 | 8-K | 2018-06-11 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On June 6, 2018, Zymeworks issued a press release announcing the filing of a preliminary prospectus supplement in connection with the issuance and sale of 5,400,000 of the Company’s common shares (the “Offering”), which was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com (the “Launch Press Release”). 8.01 On June 14, 2018, Zymeworks filed a material change report regarding the launch, pricing and closing of the Offering, as described in the Launch Press Release, the Pricing Press Release and the Closing Press Release with the Canadian securities regulatory authorities. | form8k.htm |
| 2018-06-08 | 8-K | 2018-06-08 | 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.07 On June 7, 2018, Zymeworks Inc. (the “Company”), held its 2018 annual and special meeting of shareholders (the “Annual Meeting”). 8.01 On June 7, 2018, Zymeworks issued a press release announcing the voting results of its Annual Meeting, which was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. | d596822d8k.htm |
| 2018-06-08 | 8-K | 2018-06-06 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 On June 6, 2018, Zymeworks Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Citigroup Global Markets Canada Inc. and Wells Fargo Securities Canada, Ltd., as representatives of the several underwriters named in Schedule II thereto (the “Underwriters”), relating to the issuance and sale of 5,400,000 of the Company’s common shares, without par value (the “Offered Shares”), at a price to the public of US$15.75 per share (the “Offering”), which will result in approximately US$79 million of net proceeds to the Company after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. 7.01 On June 6, 2018, Zymeworks issued a press release announcing the filing of a preliminary prospectus supplement in connection with the Offering, which was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. | d589551d8k.htm |
| 2018-06-07 | 8-K | 2018-06-01 | 8.01 Other Events | 8.01 On June 1, 2018, Zymeworks issued a press release announcing the presentation of ZW25 clinical data, which was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval at www.sedar.com and with the Securities Exchange Commission (the “SEC”) on a Current Report on Form 8-K on the SEC’s Electronic Data Gathering Analysis and Retrieval system at www.sec.gov. | d596080d8k.htm |
| 2018-06-01 | 8-K | 2018-06-01 | 8.01 Other Events | 8.01 On June 1, 2018, Zymeworks Inc. announced the presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting of ZW25 clinical data by Funda Meric-Bernstam, MD, Principal Investigator for the ZW25 study at the University of Texas MD Anderson Cancer Center. | d557578d8k.htm |
| 2018-05-18 | 8-K | 2018-05-14 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On May 14, 2018, Zymeworks Inc. (“Zymeworks”) entered into a new license agreement with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) pursuant to which Daiichi Sankyo expects to research, develop and commercialize two bispecific antibodies generated through the use of the AzymetricTM and EFECTTM platforms (the “New Agreement”). 8.01 On May 14, 2018, Zymeworks issued a press release announcing the New Agreement, which was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. | d591104d8k.htm |
| 2018-05-16 | 8-K | 2018-05-16 | 7.01 Regulation FD Disclosure | 7.01 On May 16, 2018, Zymeworks Inc. (“Zymeworks”), a corporation governed by the Business Corporations Act (British Columbia) (the “Act”), filed in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”), in compliance with the Act, a management proxy circular in respect of its annual and special shareholders’ meeting. | d527862d8k.htm |
| 2018-05-10 | 8-K | 2018-05-10 | 8.01 Other Events | 8.01 On May 10, 2018, the Company announced that management will present at the upcoming UBS Global Healthcare Conference taking place May 21-23, 2018 in New York, NY. | form8k.htm |
| 2018-05-01 | 8-K | 2018-05-01 | 2.02 Results of Operations and Financial Condition | 2.02 On May 1, 2018, Zymeworks Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2018. | d579663d8k.htm |
| 2018-04-30 | 8-K | 2018-04-30 | 8.01 Other Events | 8.01 On April 30, 2018, the Company announced that management will present at the upcoming Bloom Burton & Co. Healthcare Investor Conference taking place May 2-3, 2018 in Toronto, Canada. | form8k.htm |
| 2018-04-25 | 8-K | 2018-04-25 | 8.01 Other Events | 8.01 On April 25, 2018, the Company announced that the abstract highlighting new data from the Company's adaptive Phase 1 clinical trial for ZW25 has been selected for an oral presentation at the American Society of Clinical Oncology (ASCO) being held in Chicago from June 1 through 5, 2018. | form8k.htm |
| 2018-04-23 | 8-K | 2018-04-23 | 8.01 Other Events | 8.01 On April 23, 2018, the Company announced that Celgene Corporation has exercised its right to expand its collaboration agreement for the research, development, and commercialization of bispecific antibody therapeutics using Zymeworks’ Azymetric™ platform. | form8k.htm |
| 2018-04-18 | 8-K | 2018-04-17 | 8.01 Other Events | 8.01 On April 17, 2018, the Company announced that it presented preclinical data on ZW49, its lead bispecific antibody-drug conjugate candidate (ADC) and its ZymeLink ADC platform at the annual meeting of the American Association for Cancer Research. | form8k.htm |
| 2018-03-14 | 8-K | 2018-03-14 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On March 14, 2018, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2017. 8.01 On March 14, 2018, the Company announced that ZW49 is the first product candidate selected for clinical development utilizing technology from the Company’s 2016 acquisition of Kairos Therapeutics Inc. and its antibody-drug conjugate platform. | d548429d8k.htm |